Federal support: In guidelines released in January, the Food and Drug Administration laid out recommendations for the industry as uses of AI in the drug development process continue to increase.
Some of the recommendations include ensuring that AI technologies “adhere to relevant legal, ethical, technical, scientific, cybersecurity, and regulatory standards.”
The administration said the guidelines will “help cultivate future growth in this rapidly progressing field.”
President Donald Trump also signed an executive order in September that dedicates funds to ramping up AI innovation in the fight against pediatric cancer. The order focuses on using AI to research prevention strategies and cures for the disease.
It is notable because it is more difficult for AI to assist with pediatric cancer imaging due to the diverse anatomies of growing children and the shortage of childhood cancer data, according to Stanford University.
From the Hill: One bill to watch is the HEALTH AI Act that Lieu introduced in August. The measure would require HHS to establish a grant program to help pay for research on the use of generative AI in health care.
Lieu told us the legislation would “incentivize research” for discovering solutions to lower the administrative burden in health care so doctors and nurses can focus on delivering patient care instead of spending more time filling out paperwork.
The bill hasn’t received a vote, but it was referred to the Energy and Commerce Committee in August.